drugset / Trial / NCT06953934

A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants

NCT06953934 ↗

Phase 1 Active not recruiting 8 enrolled AbbVie
NaSingle-groupOpen-labelBasic science

Summary

The main objective of this study is to assess the safety and tolerability of ABBV-932 in healthy adult male participants.

Timeline

Start
2026-05-04
Primary completion
2026-09
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-932 Unknown — Oral

Indications

No indication recorded.